The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Bone health in cancer: ESMO Clinical Practice Guidelines
Open accessAbstract
•The clinical course of advanced cancer for many patients with bone metastases can be transformed through optimum multidisciplinary management.•Bone-targeted agents significantly reduce skeletal morbidity in patients with bone metastases across tumour types and should be part of standard treatment.•Treatment-induced bone loss increases fracture risk and may require use of a bone-targeted agent in addition to lifestyle modifications.•The addition of a bisphosphonate to standard adjuvant therapies for postmenopausal early breast cancer reduces bone recurrence and improves survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity
Coleman, R. E. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0931 · Cited by 2,488
Self-citationStopeck, A. T., Lipton, A., Body, J.-J., Steger, G. G., Tonkin, K., de Boer, R. H., Lichinitser, M., Fujiwara, Y., Yardley, D. A., Viniegra, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.7101 · Cited by 1,597
Self-citationDenosumab in men receiving androgen-deprivation therapy for prostate cancer
Smith, M. R., Egerdie, B., Toriz, N. H., Feldman, R., Tammela, T. L. J., Saad, F., Heracek, J., Szwedowski, M., Ke, C., Kupic, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809003 · Cited by 1,140
Rosen, L. S., Gordon, D., Kaminski, M., Howell, A., Belch, A., Mackey, J., Apffelstaedt, J., Hussein, M. A., Coleman, R. E., Reitsma, D. J., et al. (2003) · Cancer · doi:10.1002/cncr.11701 · Cited by 873
Self-citationEastell, R., O'Neill, T. W., Hofbauer, L. C., Langdahl, B., Reid, I. R., Gold, D. T., & Cummings, S. R. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.69 · Cited by 827
Smith, M. R., Saad, F., Coleman, R., Shore, N., Fizazi, K., Tombal, B., Miller, K., Sieber, P., Karsh, L., Damião, R., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61226-9 · Cited by 797
Self-citationCummings, S. R., Ferrari, S., Eastell, R., Gilchrist, N., Jensen, J.-E. B., McClung, M., Roux, C., Törring, O., Valter, I., Wang, A. T., et al. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3337 · Cited by 734
Dykewicz, C. A. (2001) · Clinical Infectious Diseases · doi:10.1086/321805 · Cited by 636
Hillengass, J., Usmani, S., Rajkumar, S. V., Durie, B. G. M., Mateos, M.-V., Lonial, S., Joao, C., Anderson, K. C., García-Sanz, R., Riva, E., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30309-2 · Cited by 516
Self-citationRaje, N., Terpos, E., Willenbacher, W., Shimizu, K., García-Sanz, R., Durie, B., Legieć, W., Krejčí, M., Laribi, K., Zhu, L., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30072-x · Cited by 449
Self-citationSmith, M., Parker, C., Saad, F., Miller, K., Tombal, B., Ng, Q. S., Boegemann, M., Matveev, V., Piulats, J. M., Zucca, L. E., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30860-x · Cited by 413
Fracture Risk With Multiple Myeloma: A Population-Based Study
Melton, L. J., Kyle, R. A., Achenbach, S. J., Oberg, A. L., & Rajkumar, S. V. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.041131 · Cited by 332
Hadji, P., Aapro, M. S., Body, J.-J., Gnant, M., Brandi, M. L., Reginster, J. Y., Zillikens, M. C., Glüer, C.-C., de Villiers, T., Baber, R., et al. (2017) · Journal of Bone Oncology · doi:10.1016/j.jbo.2017.03.001 · Cited by 277
Self-citationCancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST
Costelloe, C. M., Chuang, H. H., Madewell, J. E., & Ueno, N. T. (2010) · Journal of Cancer · doi:10.7150/jca.1.80 · Cited by 270
Coleman, R., Finkelstein, D. M., Barrios, C., Martin, M., Iwata, H., Hegg, R., Glaspy, J., Periañez, A. M., Tonkin, K., Deleu, I., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30687-4 · Cited by 261
Self-citationMetastatic bone disease: Pathogenesis and therapeutic options
D'Oronzo, S., Coleman, R., Brown, J., & Silvestris, F. (2019) · Journal of Bone Oncology · doi:10.1016/j.jbo.2018.10.004 · Cited by 255
Self-citationTargeted Alpha Therapy, an Emerging Class of Cancer Agents: A Review
Targeted Alpha Therapy Working Group, Parker, C., Lewington, V., Shore, N., Kratochwil, C., Levy, M., Lindén, O., Noordzij, W., Park, J., & Saad, F. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4044 · Cited by 243
Gnant, M., Pfeiler, G., Steger, G. G., Egle, D., Greil, R., Fitzal, F., Wette, V., Balic, M., Haslbauer, F., Melbinger-Zeinitzer, E., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30862-3 · Cited by 239
Shapiro, C. L., Van Poznak, C., Lacchetti, C., Kirshner, J., Eastell, R., Gagel, R., Smith, S., Edwards, B. J., Frank, E., Lyman, G. H., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01696 · Cited by 231
Self-citationBlack, D. M., Abrahamsen, B., Bouxsein, M. L., Einhorn, T., & Napoli, N. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00001 · Cited by 198
Morgan, G. J., Davies, F. E., Gregory, W. M., Bell, S. E., Szubert, A. J., Cook, G., Drayson, M. T., Owen, R. G., Ross, F. M., Jackson, G. H., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3211 · Cited by 167
Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody
von Moos, R., Costa, L., González‐Suárez, E., Terpos, E., Niepel, D., & Body, J. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.05.003 · Cited by 151
Self-citationBisphosphonates in multiple myeloma
Djulbegović, B., Wheatley, K., Ross, H. F., Clark, O. A. C., Bos, G. M. J., Goldschmidt, H., Cremer, F. W., Alsina, M., & Glasmacher, A. G. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003188 · Cited by 141
The anti-tumor effect of RANKL inhibition in malignant solid tumors – A systematic review
de Groot, A. F., Appelman‐Dijkstra, N. M., van der Burg, S. H., & Kroep, J. R. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.10.010 · Cited by 140
Barrett-Lee, P. J., Casbard, A. C., Abraham, J., Hood, K., Coleman, R. E., Simmonds, P., Timmins, H., Wheatley, D. A., Grieve, R., Griffiths, G. O., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70539-4 · Cited by 128
Self-citationCancer treatment-induced bone loss (CTIBL): Pathogenesis and clinical implications
D’Oronzo, S., Stucci, L. S., Tucci, M., & Silvestris, F. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.09.003 · Cited by 126
Targeting prostate cancer: Prostate‐specific membrane antigen based diagnosis and therapy
Wüstemann, T., Haberkorn, U., Babich, J. W., & Mier, W. (2018) · Medicinal Research Reviews · doi:10.1002/med.21508 · Cited by 125
Hoskin, P. J., Hopkins, K., Misra, V., Holt, T., McMenemin, R., Dubois, D., McKinna, F., Foran, B., Madhavan, K., MacGregor, C., et al. (2019) · JAMA · doi:10.1001/jama.2019.17913 · Cited by 120
Consensus on the utility of bone markers in the malignant bone disease setting
Coleman, R. E., Costa, L., Fred Saad, C., Cook, R. J., Hadji, P., Terpos, E., Garnero, P., Brown, J. E., Body, J., Smith, M. R., et al. (2011) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.02.005 · Cited by 109
Self-citationRole of Microenvironment on the Fate of Disseminating Cancer Stem Cells
Ingangi, V., Minopoli, M., Ragone, C., Motti, M. L., & Carriero, M. V. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00082 · Cited by 91
Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307
Gralow, J. R., Barlow, W. E., Paterson, A. H. G., Miao, J., Lew, D. L., Stopeck, A., Hayes, D. F., Hershman, D. L., Schubert, M. M., Clemons, M. J., et al. (2019) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djz215 · Cited by 78
Coleman, R. E., Hall, A., Albanell, J., Hanby, A. M., Bell, R. H., Cameron, D., Dodwell, D. J., Marshall, H. C., Jean-Mairet, J., Tercero, J.-C., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30603-4 · Cited by 69
Self-citationBone health in the elderly cancer patient: A SIOG position paper
Body, J., Terpos, E., TOMBAL, B. F., Hadji, P., Arif, A., Young, A., Aapro, M., & Coleman, R. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.10.004 · Cited by 51
Self-citationHoskin, P., Misra, V., Hopkins, K., Holt, T., Brown, G., Arnott, S., Thomas, S. S., Reczko, K., Beare, S., Lopes, A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.18_suppl.lba10004 · Cited by 43
Yang, M. X., & Yu, X. (2020) · Supportive Care in Cancer · doi:10.1007/s00520-020-05355-7 · Cited by 25
Clinical benefits of bone targeted agents in early breast cancer
Coleman, R. E. (2019) · The Breast · doi:10.1016/s0960-9776(19)31133-6 · Cited by 16
Self-citationSkeletal Metastasis Evaluation
Broski, S. M., Young, J. R., Kendi, A. T., & Subramaniam, R. M. (2018) · PET Clinics · doi:10.1016/j.cpet.2018.08.006 · Cited by 10
Research works printed but not linked: 7
- Dennis, 2012, Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer, J Clin Oncol, 30, 519, 10.1200/JCO.2011.36.5791 · doi:10.1200/jco.2011.36.5791
- Rich, 2018, Update of the systematic review of palliative radiation therapy fractionation for bone metastases, Radiother Oncol, 126, 547, 10.1016/j.radonc.2018.01.003 · doi:10.1016/j.radonc.2018.01.003
- Willeumier, 2016, Treatment of pathological fractures of the long bones, EFORT Open Rev, 1, 136, 10.1302/2058-5241.1.000008 · doi:10.1302/2058-5241.1.000008
- Coleman, 2013, Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features – an exploratory analysis of placebo-controlled trials, J Bone Oncol, 2, 70
- Otto, 2018, Medication-related osteonecrosis of the jaw: prevention, diagnosis and management in patients with cancer and bone metastases, Cancer Treat Rev, 69, 177, 10.1016/j.ctrv.2018.06.007 · doi:10.1016/j.ctrv.2018.06.007
- Saad, 2012, Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases, Ann Oncol, 23, 1341, 10.1093/annonc/mdr435 · doi:10.1093/annonc/mdr435
- Sprave, 2018, Randomized phase II trial evaluating pain response in patients with spinal metastases following stereotactic body radiotherapy versus three-dimensional conformal radiotherapy, Radiother Oncol, 128, 274, 10.1016/j.radonc.2018.04.030 · doi:10.1016/j.radonc.2018.04.030
Cited by
Gennari, A., André, F., Barrios, C. H., Cortés, J., de Azambuja, E., DeMichele, A., Dent, R., Fenlon, D., Gligorov, J., Hurvitz, S. A., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.09.019 · Cited by 1,417
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M. S., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G. S., Biganzoli, L., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.010 · Cited by 1,369
“Volume 31 - Issue 12 - 2020 The ABC panel decided to endorse the ESMO Clinical Practice Guideline (CPG) related to the use of bone-targeted agents (bisphosphonate, denosumab), which replace all previous statements regarding this subject.(99) Leptomeningeal disease (LMD) is a rare complication of breast cancer with a 5…”
Self-citationProstate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Parker, C., Castro, E., Fizazi, K., Heidenreich, A., Ost, P., Procopio, G., Tombal, B., & Gillessen, S. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.06.011 · Cited by 977
Hendriks, L. E., Kerr, K. M., Menis, J., Mok, T. S., Nestle, U., Passaro, A., Peters, S., Planchard, D., Smit, E. F., Solomon, B. J., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.12.009 · Cited by 853
Hendriks, L. E., Kerr, K. M., Menis, J., Mok, T. S., Nestle, U., Passaro, A., Peters, S., Planchard, D., Smit, E. F., Solomon, B. J., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.12.013 · Cited by 620
Metadata
- Authors
- Coleman, R., Hadji, P., Body, J.-J., Santini, D., Chow, E., Terpos, E., Oudard, S., Bruland, Ø., Flamen, P., Kurth, A., Van Poznak, C., Aapro, M., & Jordan, K.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2020-12
- Volume
- 31
- Issue
- 12
- Pages
- 1650-1663
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W3048934302
- Cited by
- 549
- References
- 38
- FWCI
- 19.33
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 365 d)
- Funders
- ESMO
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.